Clinical Trials
Participating in research is one of the most powerful things you can do to be part of tomorrow's healthcare breakthroughs. Penn State Health is always looking for people who are willing to participate in studies, so that our researchers can better understand how to diagnose, treat, and prevent diseases and conditions.
Patients are being asked to participate in this study because they may have one of the following: Brain Cancer (high-grade gliomas (HGG) that are limited to Glioblastoma Multiforme (GBM) or
...
Patients are being asked to participate in this study because they may have one of the following: Brain Cancer (high-grade gliomas (HGG) that are limited to Glioblastoma Multiforme (GBM) or
...
Patients are being asked to participate in this study because they may have one of the following: Brain Cancer (high-grade gliomas (HGG) that are limited to Glioblastoma Multiforme (GBM) or
...
This is a study for patients diagnosed with amyotrophic lateral sclerosis (ALS). The purpose of the study is to evaluate twice daily (BID) oral doses of the investigational drug SAR443820
...
This is a study for patients diagnosed with amyotrophic lateral sclerosis (ALS). The purpose of the study is to evaluate twice daily (BID) oral doses of the investigational drug SAR443820
...
The purpose of this study is to test if an experimental drug called edaravone is safe and well tolerated in patients with ALS. In this study, you will receive an
...
The primary purpose of this phase 3 clinical trial is to evaluate the safety and efficacy of ravulizumab for the treatment of participants with generalized myasthenia gravis (gMG).
...
The main purpose of this research study is to test whether an experimental drug called edaravone, is effective as treatment against ALS, and if it is safe and well tolerated
...
The main purpose of this research study is to test whether an experimental drug called edaravone, is effective as treatment against ALS, and if it is safe and well tolerated
...
This research is being done to understand how much of two drugs (dabrafenib and trametinib) is able to enter brain tumors and how well the drugs are able to turn
...